Efficacy of 1st-line therapy in patients with locally advanced and metastatic esophageal cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction. Currently, there is no consensus regarding the optimal 1st-line chemotherapy regimen for patients with locally advanced and disseminated esophageal squamous cell carcinoma. Aim. To improve treatment outcomes in patients with locally advanced and metastatic esophageal squamous cell carcinoma by optimizing first-line systemic antitumor drug therapy regimens. Materials and methods. A retrospective analysis of treatment outcomes was conducted for 271 patients with locally advanced and disseminated forms of esophageal squamous cell carcinoma. The patients received treatment with either two-drug (paclitaxel + cisplatin (TP) and paclitaxel + carboplatin (TC)) or a three-drug (docetaxel + cisplatin + 5-fluorouracil (mDCF)) combinations. The use of the three-drug mDCF combination is characterized by lower toxicity and a lower incidence of complications compared to the two-drug TP and TC regimens. Results. To date, despite their toxic effects, the investigated treatment regimens are considered safe and are most frequently prescribed for locally advanced and disseminated forms of esophageal squamous cell carcinoma. Conclusion. The modified 2-week mDCF chemotherapy regimen showed high efficacy and manageable toxicity as a 1st-line therapy for esophageal squamous cell carcinoma.
Source: Head and neck tumors (HNT)
Author: V. V. Sokolovskii
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7236859386
